WebDec 10, 2024 · In 2003, B and T lymphocyte attenuator (BTLA), the target of tifcemalimab was discovered. It is a member of the CD28 receptor family. It has a single IgSF V extracellular domain; its sequence is...

Junshi Biosciences Highlights Pipeline Advances in

WebDisclosed herein are use of IL-33 protein for the treatment, prevention, or reduction of onset or metastasis of a cancer by administering to a subject in need a therapeutically effective amount of IL-33 protein, such as human IL-33 protein, pharmaceutical compositions comprising IL-33 protein for treating cancer, and use of an agent capable of upregulating … WebHere we identify the B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. bomb philly\u0027s

BCMA-targeted immunotherapy for multiple myeloma - PubMed

WebThe immune suppressor BTLA functions in opposition to LIGHT in suppression of naïve T-cell expansion 7 and induction of T reg cells 20. BTLA is an transmembrane protein expressed on B cells, dendritic cells and naive T cells, and activated CD4+ T cells 21 . WebProvided herein are molecules, such as antibodies, that selectively bind to glycosylated BTLA (B-and T- lymphocyte attenuator) relative to unglycosylated BTLA. Methods for … WebJun 7, 2024 · Poster #230 - Phase I study of the anti-BTLA antibody icatolimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas. A single-arm, open-label, multicenter, dose ... bomb picture png